Gastrointestinal Safety Pharmacology in Drug Discovery and Development
The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Although the basic structure of the gastrointestinal tract (GIT) is similar across species, there are significant differences in the anatomy, physiology, and biochemistry between humans and laboratory animals, which should be taken into account when conducting a gastrointestinal (GI) assessment. Historically, the percentage of cases of drug attrition associated with GI-related adverse effects is small; however, this incidence has increased over the last few years. Drug-related GI effects are very diverse, usually functional in nature, and not limited to a single pharmacological class. The most common GI signs are nausea and vomiting, diarrhea, constipation, and gastric ulceration. Despite being generally not life-threatening, they can greatly affect patient compliance and quality of life. There is therefore a real need for improved and/or more extensive GI screening of candidate drugs in preclinical development, which may help to better predict clinical effects. Models to identify drug effects on GI function cover GI motility, nausea and emesis liability, secretory function (mainly gastric secretion), and absorption aspects. Both in vitro and in vivo assessments are described in this chapter. Drug-induced effects on GI function can be assessed in stand-alone safety pharmacology studies or as endpoints integrated into toxicology studies. In silico approaches are also being developed, such as the gut-on-a-chip model, but await further optimization and validation before routine use in drug development. GI injuries are still in their infancy with regard to biomarkers, probably due to their greater diversity. Nevertheless, several potential blood, stool, and breath biomarkers have been investigated. However, additional validation studies are necessary to assess the relevance of these biomarkers and their predictive value for GI injuries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“also highlighting species specific susceptibilities (Al-Saffar et al., 2015; Dalgaard, 2015).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Al-Saffar et al., 2015
Citations
Cites
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
(2010) · Cited by 1,697
Kararli, T. T. (1995) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510160502 · Cited by 1,459
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
A migrating electric complex of canine small intestine
Szurszewski, J. (1969) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1969.217.6.1757 · Cited by 854
Vantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815
Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization
Kerns, E. H., & Di, L. (2016) · Cited by 784
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
Goyal, R. K., & Hirano, I. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341707 · Cited by 775
Research works printed but not linked: 4
- Anon (1995) Guidelines for general pharmacology studies—Japanese guidelines for non-clinical studies of drugs manual, pp. 71-80. Eds. Nippo Yakuji, Ltd
- Kerns E, Di L (eds) (2008) Drug-like properties: concepts, structure design and methods, 1st edn. Academic, London
- Redfern WS, Ewart L, Hammond TG, Bialecki R, Kinter L, Lindgren S, Pollard CE, Roberts R, Rolf M, Valentin J-P (2010) Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114(S1):1081
- Wood JG, Cheung LY (1996) Gastrointestinal secretion. In: Gregerson H, Lindkaer Jensen S, Moody F, Shokouh-Amari M (eds) Essentials of experimental surgery: gastroenterology (chapter 28). Harwood Academic, Amsterdam, pp 1–21
Cited by
Avila, A. M., Bebenek, I., Bonzo, J. A., Bourcier, T., Davis Bruno, K. L., Carlson, D. B., Dubinion, J., Elayan, I., Harrouk, W., Lee, S.-L., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104662 · Cited by 196
Peters, M. F., Choy, A. L., Pin, C., Leishman, D. J., Moisan, A., Ewart, L., Guzzie-Peck, P. J., Sura, R., Keller, D. A., Scott, C. W., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc01107b · Cited by 76
Bringing microbiome-drug interaction research into the clinic
Guthrie, L., & Kelly, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.009 · Cited by 83
Groh, K. J., Geueke, B., & Muncke, J. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.08.023 · Cited by 72
“…for the assessment of intestinal permeability in vivo include histological examinations, absorption tests with oligosaccharides, and measurement of biomarkers such as blood levels of citrulline or bacterial lipopolysaccharides (Al-Saffar et al., 2015; Bischoff et al., 2014; Harrison et al., 2004).”
BackgroundHuman 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea
Peters, M. F., Landry, T., Pin, C., Maratea, K., Dick, C., Wagoner, M. P., Choy, A. L., Barthlow, H. G., Snow, D., Stevens, Z., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy268 · Cited by 68
Metadata
- Authors
- Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P.
- Affiliations
- UCB Pharma (Belgium) (BE)
- Eli Lilly (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Valentin, J.-P.
- ORCID
- Delaunois, Annie
- Venue
- Handbook of experimental pharmacology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2015
- Volume
- 229
- Pages
- 291-321
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W1923919220
- Cited by
- 29
- References
- 139
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 5 · 2022: 2 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 1 · 2016: 2
- FWCI
- 14.13
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- drug-induced gastrointestinal injury, drug attrition, nausea and vomiting, diarrhea, constipation, gastric ulcer, gastrointestinal motility, gastric secretion, drug absorption, preclinical drug screening, in vitro and in vivo models, gut-on-a-chip
- MeSH terms
- Animals, Drug and Narcotic Control, Drug Evaluation, Preclinical, Gastric Emptying, Gastrointestinal Motility, Humans, Intestinal Absorption, Biomarkers, Gastrointestinal Tract, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal Safety Pharmacology in Drug Discovery and Development. https://app.cochat.ai/papers/10.1007/978-3-662-46943-9_12
- The paper
- Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P. (2015). Gastrointestinal Safety Pharmacology in Drug Discovery and Development. Handbook of experimental pharmacology. https://doi.org/10.1007/978-3-662-46943-9_12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.